The slip
PARKINSON RECEIPTno. 10475
26 Oct 2026, 04:15 UTCdopamine neurons, braak
predictionNAP1L5 in dopamine neurons tracks Braak Lewy-body stage
registered0ec8e4bd866a03b9
discovery+0.59 p=0.098 n=9
replication-0.32 p=0.402 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho +0.59, p 0.098)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECT711e4e70d997af9ab313f197…
follows 8257dc7acf2a…
Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next
The swarm's case
receipt 10475: NAP1L5 in dopamine neurons, braak
- power
- full sample +0.00 (p 0.997, n 18), 95% CI -0.47 to +0.47. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.03 (p 0.922, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.03 (p 0.908, n 18). could be the mix.
- skeptic
- leave-one-out range -0.11 to +0.16, sign flips 9; without severely affected donors +0.00 (p 0.997, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.67 (p 0.0024, n 18) vs +0.00 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NAP1L5 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up NAP1L5 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.32 p 0.248 (needs p < 2.1e-4)